67results about How to "Wide host range" patented technology

Affinity separation compositions and methods are disclosed for separating targets from complex mixtures. Affinity reagents are bound to a solid support oriented in a manner to facilitate the activity of the affinity reagents which are capable of binding specific targets by affinity recognition. Affinity reagents include IgY antibodies, proteins, peptides, nucleotides and polymers. Targets include proteins, protein-protein complexes, protein-nucleotide complexes, nucleotides, cells and subcellular organelles.

The invention discloses COVID-19-S-RBD virus-like particles and vaccine, and preparation methods of the virus-like particles and the vaccine. pET28a-CuMVTT recombinant plasmid is constructed after a CuMVTT gene is used to connect pET28a plasmid; pFUSE-COVID-19-S-RBD recombinant plasmid is constructed by a COVID-19-S-RBD gene and pFUSE plasmid; the recombinant plasmid is respectively transferred into the expression strains of escherichia coli and the expression cell lines of 293 F cells; the expression strains of escherichia coli are cultivated, biomass is separated through centrifugation, andthe virus-like particles are obtained; COVID-19-S-RBD protein is obtained by cultivating the expression cell lines of the 293 F cells; and the virus-like particles are coupled to the COVID-19-S-RBD through a chemical coupling reagent SMPH. The virus-like particles and the vaccine can be easily obtained through bacteria culture; yield can be higher than that of chimeric expression; and thus, industrial production and fast immunity can be achieved.

The present invention provides compositions and methods for affinity separation of targets from mixtures. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use.

The invention relates to enterohaemorrhagic escherichia coli phage and an application thereof. The enterohaemorrhagic escherichia coli phage is characterized in that the preservation number of a phage strain is CCTCC NO:M 2016539, and the phage strain is preserved at the China Center for Type Culture Collection at Wuhan university in China on September 29, 2016, and is classified and named asenterohaemorrhagic coliphage vB-ECM-MIE, entero-haemorrhagic-Escherichia-coli-O157:H7 phage vB-ECM-MIE. The enterohaemorrhagic escherichia coli phage has efficient sterilization capacity on EHEC.

The invention discloses an anti-pathogen hyperimmune yolk antibody, an AAV vector vaccine based preparation method and a preparation. The preparation method of the hyperimmune yolk antibody comprisesthe steps of selecting a first gene sequence containing an antigen protein fragment from a genomic sequence of a pathogen, and synthesizing a pathogen protective antigen gene through codon optimization; packaging a recombinant AAV vector vaccine carrying the antigen gene; and immunizing a healthy laying hen, and preparing the yolk antibody from a hen egg of the laying hen. According to the method,recombinant adeno-associated viruses with high safety, quick and simple packaging, low cost and stable expression are used as the vector vaccine for expressing protective antigen proteins of virusesor bacteria, the hen egg can be collected by immunizing the healthy laying hen once, the antivirus or antibacterial yolk antibody as an active component in yolk is extracted, and the antibody is natural immune globulin and can kill the viruses or bacteria and prevent viral or bacterial infection.

The invention belongs to the technical field of research and development of Vibrio alginolyticus phages and particularly relates to a wide-lytic-spectrum Vibrio alginolyticus phage, composition thereof, and a kit. The wide-lytic-spectrum Vibrio alginolyticus phage is Vibrio alginolyticus phage VAP7 collected under CCTCC NO: M 2018767. The inventio also discloses application of the Vibrio alginolyticus phage, a Vibrio alginolyticus phage composition, or a reagent or a kit containing the Vibrio alginolyticus phage or the Vibrio alginolyticus phage composition in the killing and/or prevention ofVibrio microbes. The Vibrio alginolyticus phage herein has a wide host range, has high toxicity to host bacteria under low concentration, can well propagate on nonpathogenic bacterial hosts, and is suitable for large-scale industrial production. Good strain resources can be provided for the application of phagotherapy.

The invention belongs to the technical field of microorganism prevention and treatment, and particularly relates to a vibrio parahaemolyticus bacteriophage VP-HYP MCS-1 and bdellovibrio bacteriovorusHalobacterovoraxsp.MCS-1 composition and application thereof to prevention and treatment of prawn pathogenic vibrio parahaemolyticus infection. The vibrio parahaemolyticus bacteriophage is vibrio parahaemolyticus bacteriophage VP-HYPMCS-1, is preserved in China General Microbiological Culture Collection Center, and has a preservation number of CGMCC No.199693. The vibrio parahaemolyticus bacteriophage is a vibrio parahaemolyticus bacteriophage VP-HYPMCS-1. The bdellovibrio parahaemolyticus is bdellovibrio parahaemolyticus Halobacterovoraxsp.MCS-1, is preserved in the China General Microbiological Culture Collection Center (CGMCC), and has a preservation number of CGMCC No.199694. The invention also discloses a preparation method of the bdellovibrio parahaemolyticus strain. The virulent bacteriophage VP-HYP MCS-1 obtained through separation is high in host specificity and has cracking and killing effects on vibrio parahaemolyticus; the bdellovibrio bacteriovorus Halobacterium ovalax sp.MCS-1 is obtained through separation, the host spectrum of the bdellovibrio bacteriovorus Halobacterium ovalax sp.MCS-1 is wide, and the bdellovibrio bacteriovorus Halobacterium ovalax sp.MCS-1 has cracking and killing effects on various vibrios including vibrio parahaemolyticus; the vibrio parahaemolyticus bacteriophage and bdellovibrio bacteriovorus provided by the invention have good application prospects in prevention and control of prawn pathogenic vibrio parahaemolyticus infection.

The invention discloses a replacement method of influenza A virus antigenic determinant. The method aims at the position of antigenic determinant to utilize and design restriction enzyme cutting site, thus realizing that the entire or part of the sequence of antigenic determinant of the strains of influenza in the same subtype or different subtypes can be changed; and an eight-plasmid reverse gene operation system is used to rescue the recombinant influenza virus of which antigenicity is through artificial directed change, and the method has great practical value in the quick preparation of attenuated live vaccine of influenza virus and repeated use of virus vector in gene therapy.

The invention provides a transient transfection reagent and a use thereof. The transfection efficiency of the transfection reagent is high and stable and is equivalent to the transfection efficiency of Lipofectamine 3000 (hereinafter referred to as lipo3000). The transient transfection reagent has high transfection efficiency both in plasmid single transfection and co-transfection and has very small cytotoxicity. The transient transfection reagent can be simply operated. Compared with lipo3000, the transient transfection reagent is free of plasmid dilution and reagent transfection, realizes transfection in 10min, has high solution stability, can be stored at a temperature of 4 DEG C for a long time, has a low cost, very high transfection efficiency and high stability, can be operated easily, is suitable for a wide range of host cells, is not influenced by antibiotics of the culture medium in transfection efficiency and is an excellent choice for a lab where a lot of transient transfection experiments are carried out.

The invention discloses a bacillus gene knockdown carrier plasmid pBD1 based on dCas9, construction and application. The plasmid pBD1 is constructed by utilizing multiple molecular biology methods such as PCR, enzyme digestion, enzyme linking, sequencing and transformation, the plasmid pHY300-dCas9-sgRNA (pBD1) containing IPTG an inducible Pgrac promoter, dCas9 and sgRNA is constructed on the basis of bacillus expression vector, and the plasmid is theoretically suitable for a broad bacillus range because of having a large promoter strength and a wide host range.

The invention discloses a recombinant rat phospholipase Cγ2 adenovirus, which is obtained by inserting the rat phospholipase Cγ2 gene into an adenovirus shuttle plasmid pHBAd‑MCMV‑GFP containing the adenovirus genome, the rat phospholipase Cγ2 gene The nucleotide sequence is shown in SEQ ID NO.1. The present invention also provides the construction method and application of the above-mentioned recombinant rat phospholipase Cγ2 adenovirus. Aiming at the promoting effect of PLCγ2 in cancer cell apoptosis, the present invention constructs a PLCγ2 recombinant adenovirus to replace the gene model, which can regulate the growth of cancer cells in a targeted manner, and the recombinant rat phospholipase Cγ2 adenovirus can stably express rat phospholipids Enzyme Cγ2, with high virus titer and significant pro-apoptotic effect; recombinant adenovirus and the rat phospholipase Cγ2 expressed by it can significantly inhibit cell proliferation and promote apoptosis of rat liver tumor cells, and can be used for the prevention of liver tumors And treatment provides new treatment ideas.

Compositions and methods for the therapy and diagnosis of cancer, such as pancreatic cancer, are disclosed. Compositions may comprise one or more pancreatic tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a pancreatic tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as pancreatic cancer. Diagnostic methods based on detecting a pancreatic tumor protein, or mRNA encoding such a protein, in a sample are also provided.

The invention discloses a pig endogenous retrovirus vector and a construction method and application thereof. The vector constructed in the invention has the following advantages of: efficiently infecting various cells and having wide host range, efficiently integrating a target gene into a genome of the infected cells and expressing in a high level, having efficient infection characteristic, transmitting a recombinant target gene to an entire cell colony, combining with a tissue specificity promoter and probably fulfilling the aims of positioning and expressing the target gene in specific tissues or organs, along with higher suitability for gene therapy and other application.

A recombined type 1 herpes simplex virus (Simplexvirus Herps simplexvirus 1rHSV-1Delta34.5/lacZ), its preparation method and the application in antineoplastic are disclosed. The preparation process is: obtaining the beta-galactosidase expression box and purifying, constructing medium carrier IpFL, constructing medium carrier II pBL, constructing transfer carrier pIL and obtaining recombined virus. The apoptosis inhibiting gene icp34.5, a neurotoxic gene, is inactivateed by the reporter gene lacZ insertion. The recombined type 1 herpes simplex virus can only be replicated in the tumor cell, therefore, it is capable of killing tumor cell effectively, being safe for normal cell and tissue.

The invention relates to a recombinant virus expressing a VP2 gene of a bluetongue virus type 16 and a construction method and application of the recombinant virus. The recombinant virus includes a virus vector and a recombinant shuttle plasmid which has the VP2 gene of the bluetongue virus type 16 and is packaged in the virus vector, and the sequence of the VP2 gene of the bluetongue virus type 16 is shown in SEQ ID NO.1. Accordingly, the recombinant virus rVTT-VP2 expressing the VP2 gene of the bluetongue virus type 16 (BTV-16) is constructed and screened for the first time at home and abroad, and identified through a molecular biological method. By means of ten times of repeated plaque purification and 20 times of continuous passage, PCR identification results show that the VP2 gene isintegrated into a genome of the recombinant vaccinia virus, and a TK gene cannot be amplified; it is indicated that the recombinant vaccinia virus rVTT-VP2 genetic stability is good, and the virus ispurified.